SCHEMBL19523052

SCHEMBL19523052

CSCNC(=O)C1CCCCC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NAAA Q02083 1/20 0.56
▸ EPHX1 P07099 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ HDAC8 Q9BY41 1/20 0.48
▸ HDAC6 Q9UBN7 1/20 0.48
▸ POLB P06746 1/20 0.46
▸ CTSL P07711 1/20 0.44
▸ CTSB P07858 1/20 0.44
▸ CTSK P43235 1/20 0.44
▸ TSHR P16473 2/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ KEAP1 Q14145 1/20 0.41
▸ NFE2L2 Q16236 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19669659 0.81 NAAA (0.61) NAAAEPHX1SMN1; SMN2HSD17B10HDAC8
SCHEMBL61528 0.81 NAAA (0.61) NAAAEPHX1SMN1; SMN2HSD17B10HDAC8
SCHEMBL7484827 0.81 NAAA (0.61) NAAAEPHX1SMN1; SMN2HSD17B10HDAC8
SCHEMBL1810307 0.79 SMN1; SMN2 (0.61) NAAAEPHX1SMN1; SMN2HSD17B10HDAC8
SCHEMBL19002780 0.78 NAAA (0.54) NAAAEPHX1SMN1; SMN2HSD17B10HDAC8
SCHEMBL517349 0.78 NAAA (0.73) NAAAEPHX1SMN1; SMN2HSD17B10HDAC8
SCHEMBL8690270 0.78 NAAA (0.73) NAAAEPHX1SMN1; SMN2HSD17B10HDAC8
SCHEMBL19322417 0.78 CHRNB2 (0.44) NAAASMN1; SMN2HSD17B10TSHRKMT2A
SCHEMBL19757607 0.76 EPHX1 (0.65) NAAAEPHX1SMN1; SMN2HSD17B10HDAC8
SCHEMBL3184451 0.76 NAAA (0.66) NAAAEPHX1SMN1; SMN2HSD17B10HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802958-B2 Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease LYCERA CORPORATION (US) 2017-10-31 — — US disclosed
Send feedback